Keyword: Lemtrada

Sanofi is shelling out $315 million to settle claims it delayed the MS drug Lemtrada, acquired in its Genzyme buyout, to avoid follow-up payments.

After a tough year in the competitive MS field, Sanofi’s Lemtrada could hardly afford another setback. But that’s exactly what it got.

Rejected in 2011, Mavenclad won FDA approval with a label that's not ideal—but that doesn't necessarily hurt its blockbuster odds, says one analyst.

Sanofi’s Lemtrada is already struggling in a tough multiple sclerosis field, and a new FDA safety warning isn’t going to help matters.

Sanofi has struggled to rev up multiple sclerosis therapy Lemtrada, but some new long-term data might help it win over doctors and patients.

Sanofi's Q3 results are feeding fears that its innovation engine may not be able to outpace the decline in its aging diabetes unit.

Some closely watched new drugs grabbed the spotlight at the American Academy of Neurology meeting this week, and plenty of other therapies put up results worth noting.

The new multiple sclerosis med Roche has been anticipating—and the market shake-up other drugmakers have been dreading—is here.

U.S. drug price watchdog ICER is out with its final multiple sclerosis med assessment—and drugmakers likely won’t agree with its conclusions.

Roche’s much-anticipated multiple sclerosis drug Ocrevus (ocrelizumab) has topped up with more competitive data that could help it gain a quick hold in the hotly contested market.